Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;4(12):e2136802.
doi: 10.1001/jamanetworkopen.2021.36802.

Statin Discontinuation and Cardiovascular Events Among Older People in Denmark

Affiliations

Statin Discontinuation and Cardiovascular Events Among Older People in Denmark

Wade Thompson et al. JAMA Netw Open. .

Erratum in

  • Data Errors in Results Section.
    [No authors listed] [No authors listed] JAMA Netw Open. 2022 Jan 4;5(1):e220010. doi: 10.1001/jamanetworkopen.2022.0010. JAMA Netw Open. 2022. PMID: 35089357 Free PMC article. No abstract available.

Abstract

Importance: Statin use is common in older persons. Given uncertainties in ongoing benefit, changes in health status, and shifting goals of care and preferences, statin discontinuation may be considered in some older persons, although there is currently little evidence to guide this decision.

Objective: To evaluate the association between statin discontinuation and the rate of major adverse cardiovascular events (MACE) among people aged 75 years or older who receive long-term statin treatment.

Design, setting, and participants: This cohort study included all persons in Denmark aged 75 years or older who were treated with statins for at least 5 consecutive years as of January 1, 2011. Participants were followed up until December 31, 2016. Data were analyzed from July to November, 2020.

Exposure: Statin discontinuation.

Main outcomes and measures: Rate of occurrence of MACE and its components (myocardial infarction, ischemic stroke or transient ischemic attack, coronary revascularization, and death due to myocardial infarction or ischemic stroke) in persons continuing statins compared with those discontinuing statins. Confounding adjustment was done using inverse probability of treatment weighting. Analyses were conducted separately for primary prevention (no history of cardiovascular disease) and secondary prevention (history of cardiovascular disease).

Results: The study included 67 418 long-term statin users, including 27 463 in the primary prevention analysis (median age, 79 years [IQR, 77-83 years]; 18 134 [66%] female) and 39 955 in the secondary prevention analysis (median age, 80 years [IQR, 77-84 years]; 18 717 [47%] female). In both primary and secondary prevention analyses, the rate of MACE was higher among persons who discontinued statins compared with those who continued statins. In the primary prevention cohort, the weighted rate difference was 9 per 1000 person-years (95% CI, 5-12 per 1000 person-years) and the adjusted sub-hazard ratio was 1.32 (95% CI, 1.18-1.48), corresponding to 1 excess MACE per 112 persons who discontinued statins per year. In the secondary prevention cohort, the weighted rate difference was 13 per 1000 person-years (95% CI, 8-17 per 1000 person-years) and the adjusted sub-hazard ratio was 1.28 (95% CI, 1.18-1.39), corresponding to 1 excess MACE per 77 persons who discontinued statins per year.

Conclusions and relevance: In this cohort study, among older adults receiving long-term statin treatment, discontinuation of statins was associated with a higher rate of MACE compared with statin continuation in both the primary and the secondary prevention cohorts. These findings suggest a need for robust evidence from randomized clinical trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Pottegård reported receiving grants from Alcont, Almirall, Astellas, AstraZeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, and LEO Pharma outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Cumulative Incidence Curve for the Outcome of Major Adverse Cardiovascular Events in the Primary Prevention Cohort
Figure 2.
Figure 2.. Cumulative Incidence Curve for the Outcome of Major Adverse Cardiovascular Events in the Secondary Prevention Cohort

Similar articles

Cited by

References

    1. Thompson W, Pottegård A, Nielsen JB, Haastrup P, Jarbøl DE. How common is statin use in the oldest old? Drugs Aging. 2018;35(8):679-686. doi:10.1007/s40266-018-0567-x - DOI - PubMed
    1. Gulliford M, Ravindrarajah R, Hamada S, Jackson S, Charlton J. Inception and deprescribing of statins in people aged over 80 years: cohort study. Age Ageing. 2017;46(6):1001-1005. doi:10.1093/ageing/afx100 - DOI - PMC - PubMed
    1. Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21(3):217-230. doi:10.1111/j.1472-8206.2007.00473.x - DOI - PubMed
    1. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605-609. doi:10.1001/archinte.166.6.605 - DOI - PubMed
    1. Hawley CE, Roefaro J, Forman DE, Orkaby AR. Statins for primary prevention in those aged 70 years and older: a critical review of recent cholesterol guidelines. Drugs Aging. 2019;36(8):687-699. doi:10.1007/s40266-019-00673-w - DOI - PMC - PubMed

MeSH terms

Substances